Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Pramlintide

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

AstraZeneca · Phase 2 · Completed · Enrollment 177

NCT00392925

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Placebo and Metreleptinn/rn/rn/rn/r
Pramlintide Acetate and Placebon/rn/rn/rn/r
Pramlintide Acetate and Metreleptinn/rn/rn/rn/r
Lead-In Periodn/rn/rn/rn/r

Not shown

  • Placebo and Metreleptin: endpoint not reported
  • Pramlintide Acetate and Placebo: endpoint not reported
  • Pramlintide Acetate and Metreleptin: endpoint not reported
  • Lead-In Period: endpoint not reported